HERON THERAPEUTICS, INC. /DE/
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $154.9M | $144.3M | $127.0M | $107.7M | $86.3M |
| Cost of revenue | $41.3M | $38.6M | $65.1M | $54.9M | $46.0M |
| Gross profit | $113.6M | $105.6M | $61.9M | $52.8M | — |
| Research and development | $12.4M | $16.7M | $39.1M | $82.7M | $130.8M |
| Operating income | -$2.5M | -$11.5M | -$110.6M | -$174.7M | -$217.8M |
| Interest expense | $9.6M | $6.0M | $3.9M | $2.5M | $2.4M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$20.2M | -$13.6M | -$110.6M | -$182.0M | -$220.7M |
| Balance Sheet | |||||
| Cash and equivalents | $28.6M | $25.8M | $28.7M | $15.4M | $90.5M |
| Current assets | $238.1M | $209.0M | $188.8M | $205.4M | $254.4M |
| Total assets | $255.9M | $233.1M | $222.5M | $251.0M | $305.7M |
| Current liabilities | $96.1M | $91.5M | $79.7M | $82.4M | $71.1M |
| Total liabilities | $241.5M | $266.8M | $256.5M | $237.4M | $228.1M |
| Stockholders' equity | $14.3M | -$33.7M | -$34.0M | $13.6M | $77.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$27.6M | -$22.5M | -$58.8M | -$146.9M | -$203.4M |
| Depreciation and amortization | $2.3M | $2.5M | $2.9M | $2.9M | $3.0M |
| Stock-based compensation | $10.3M | $13.0M | $32.9M | $43.0M | $46.9M |
| Capital expenditure | $317,000 | $1.7M | $1.5M | $1.8M | $3.0M |
| Free cash flow | -$27.9M | -$24.2M | -$60.3M | -$148.7M | -$206.4M |
| Impairments | — | — | $617,000 | $209,000 | $478,000 |
Shares outstanding 189.3M · Free float 75.6%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.